Dr. Amandeep Godara, MD

Dr. Godara practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Godara's NPI, 1487094066, was assigned on June 27, 2013. Dr. Godara holds Utah license 11793611-1205.

Dr. Godara's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Godara's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Godara is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Godara to 4 more hospitals, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Godara practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Godara's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Godara's licenses on file in 2 states: Utah and Massachusetts.

CMS data shows 1,418 Medicare services from Dr. Godara across 9 procedure codes in 2024, for 289 Medicare patients. Medicare paid $80,236 for them.

CMS counts 289 Medicare patients who saw Dr. Godara in 2024. The largest group is 65 to 74, with 150 patients. 75% of them have high blood pressure, and 58% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Godara's median patient age at 72, with 56% women.

In 2024, Dr. Godara wrote 1,133 Medicare Part D claims for 132 patients. 63% of them were for generic drugs. CMS names the drug for 923 of them, across 17 drugs with 11 or more claims each, at $4,742,685 in total drug cost. In 2023, CMS named 708 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Godara for performance year 2024, reported as part of a group. Dr. Godara accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Godara as offering telehealth.

Dmand AI links 35 papers to Dr. Godara, published from 2018 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Multiple Myeloma, Amyloid Neuropathies, Familial and Immunoglobulin Light-chain Amyloidosis. Dr. Godara has published most often in Am J Hematol. Dr. Godara's most frequent co-authors are Raymond L. Comenzo, MD, Cindy Iris Varga, MD and Brian Lee McClune, DO.

CMS Open Payments shows 31 general payments to Dr. Godara from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Janssen Pharmaceuticals, Inc paid the most, $5,136. It also lists 3 research payments totaling $143 in 2025, naming 2 clinical trials.